002019.SZ
002019.SZ
CNE000001K65
YIFAN PHARM
Loading chart...

Company Profile

Yifan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products, vitamins, and polymer materials in China, South Korea, the Philippines, Vietnam, Italy, Thailand, and internationally. It offers pharmaceutical products, such as biopharmaceuticals, chemical drugs, and traditional Chinese medicines; vitamin products, including vitamin B5 and provitamin B5; and active pharmaceutical ingredients. The company was formerly known as Yifan Xinfu Pharmaceutical Co., Ltd. and changed its name to Yifan Pharmaceutical Co., Ltd. in October 2016. Yifan Pharmaceutical Co., Ltd. was founded in 2000 and is headquartered in Hangzhou, China.

Related stocks

300357.SZ
300357.SZ • China
WOLWO PHARMA
19.99 CNY
1.57B USD 1Y -30.7%
300181.SZ
300181.SZ • China
ZUO LI YAO YE
13.25 CNY
1.39B USD 1Y -25.8%
600771.SS
600771.SS • China
GUANGYUYUAN CHINESE HERBAL MEDI
14.38 CNY
1.05B USD 1Y -24.5%
600713.SS
600713.SS • China
NANJING PHARMACEUTICAL GP CO LT
5.14 CNY
1.01B USD 1Y +3.6%
RUBICON.NS
RUBICON.NS • India
RUBICON RESEARCH LIMITED
1,548.5 INR
2.65B USD
PFIZER.NS
PFIZER.NS • India
PFIZER LTD
3,808.2 INR
1.8B USD 1Y -27.7%
4536.T
4536.T • Japan
SANTEN PHARMACEUTICAL CO
1,684 JPY
3.42B USD 1Y +7.8%
H02.SI
H02.SI • Singapore
Haw Par
12.77 SGD
2.21B USD 1Y -13.6%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
35.5% p.a.
Max Drawdown (5Y)
-56.0%
Sharpe Ratio (5Y)
-0.36
Beta Factor
0.47
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (35.5% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -72.0% in the extended horizon.
ende